Want to see JP:9341 full AI Analyst Report?
Top Page
GENOVA Inc.
(9341)
Select Model
Select Model
Rating:61Neutral
Price Target:
¥650.00
▲(11.68% Upside)
Action:Reiterated
Date:08/17/26
The score is held back primarily by weakened 2026 fundamentals—sharp margin/ROE compression and a major deterioration in cash generation with negative free cash flow—despite strong revenue growth and modest leverage. Technicals are modestly supportive with price above key longer-term averages, and valuation is a relative strength given the solid dividend yield and reasonable P/E.
Positive Factors
Sustained Revenue Growth
Revenue growth remains strong and has continued across multiple years, indicating sustained demand and expanding market reach. Continued scale could support stronger competitive positioning and improve operating leverage over the next several quarters.
Negative Factors
Sharp Margin Compression
The broad deterioration in gross, operating, and net margins signals weaker profitability and reduced earnings quality. Unless reversed, structurally lower margins could limit operating leverage, reduce resilience, and make future earnings less predictable.
Read all positive and negative factors
Positive Factors
Negative Factors
Sustained Revenue Growth
Revenue growth remains strong and has continued across multiple years, indicating sustained demand and expanding market reach. Continued scale could support stronger competitive positioning and improve operating leverage over the next several quarters.
Read all positive factors
GENOVA Inc. (9341) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥11.26B
Dividend Yield4.74%
Average Volume (3M)127.01K
Price to Earnings (P/E)18.1
Beta (1Y)0.77
Revenue Growth36.94%
EPS Growth-31.50%
CountryJP
Employees529
SectorGeneral
Sector StrengthN/A
IndustryMedical - Healthcare Information Services
Share Statistics
EPS (TTM)35.97
Shares Outstanding17,838,100
10 Day Avg. Volume126,090
30 Day Avg. Volume127,006
Financial Highlights & Ratios
PEG Ratio-0.43
Price to Book (P/B)1.38
Price to Sales (P/S)0.82
P/FCF Ratio-202.80
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)157.5
Revenue Forecast (FY)¥15.40B
GENOVA Inc. Business Overview & Revenue Model
Company Description
Operating within Japan, GENOVA, Inc. focuses on the digital healthcare market, providing both medical platform services and smart clinic solutions. Its offerings include Medical Doc, a comprehensive online platform that distributes diverse content...
How the Company Makes Money
null...
GENOVA Inc. Financial Statement Overview
Summary
Income Statement
58
Neutral
Balance Sheet
76
Positive
Cash Flow
34
Negative
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 12.77B | 11.57B | 10.01B | 8.68B | 6.51B | 4.80B |
| Gross Profit | 6.76B | 6.47B | 7.38B | 6.55B | 4.79B | 3.50B |
| EBITDA | 514.06M | 543.85M | 2.11B | 2.38B | 1.79B | 1.09B |
| Net Income | 623.48M | 275.40M | 1.41B | 1.73B | 1.26B | 686.27M |
Balance Sheet | ||||||
| Total Assets | 11.31B | 10.26B | 8.53B | 8.20B | 5.41B | 2.82B |
| Cash, Cash Equivalents and Short-Term Investments | 5.08B | 5.32B | 5.87B | 5.97B | 3.86B | 1.65B |
| Total Debt | 1.77B | 735.71M | 20.84M | 377.78M | 28.25M | 163.50M |
| Total Liabilities | 5.16B | 3.36B | 1.53B | 2.16B | 1.37B | 1.33B |
| Stockholders Equity | 6.15B | 6.90B | 7.00B | 6.04B | 4.04B | 1.49B |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | -46.98M | 1.06B | 1.77B | 1.11B | 513.36M |
| Operating Cash Flow | 0.00 | 53.85M | 1.19B | 1.82B | 1.20B | 623.77M |
| Investing Cash Flow | 0.00 | -809.75M | -275.93M | -94.24M | -113.45M | -179.06M |
| Financing Cash Flow | 0.00 | 199.63M | -1.01B | 376.82M | 1.13B | 59.88M |
GENOVA Inc. Technical Analysis
Positive
582.00
Price Trends
613.20
Positive
589.70
Positive
575.49
Positive
Market Momentum
5.68
Negative
55.42
Neutral
72.87
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:9341, the sentiment is Positive. The current price of 582 is below the 20-day moving average (MA) of 625.10, below the 50-day MA of 613.20, and above the 200-day MA of 575.49, indicating a bullish trend. The MACD of 5.68 indicates Negative momentum. The RSI at 55.42 is Neutral, neither overbought nor oversold. The STOCH value of 72.87 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:9341.
GENOVA Inc. Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
61 Neutral | ¥11.26B | 18.13 | ― | 5.30% | 36.94% | -31.50% | |
59 Neutral | ¥88.52B | 44.69 | 6.35% | ― | 24.03% | 34.50% | |
58 Neutral | ¥8.16B | 34.66 | ― | ― | 27.65% | -28.38% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
45 Neutral | ¥2.15B | -4.11 | ― | ― | 14.84% | 30.67% |
* General Sector Average
JP:9341
GENOVA Inc.
633.00
7.79
1.25%
JP:4480
Medley
2,687.00
205.00
8.26%
JP:4438
Welby Inc.
257.00
-77.00
-23.05%
JP:9218
Mental Health Technologies Co. Ltd.
784.00
-52.33
-6.26%
JP:366A
Wellness Communications Corporation
1,148.00
-389.12
-25.31%
GENOVA Inc. Corporate Events
Genova Returns to Profit as Sales Surge and New Subsidiary Added
Aug 10, 2026
Genova Inc. reported a sharp 64.7% year-on-year increase in net sales to ¥3.06 billion for the quarter ended June 30, 2026, while operating and ordinary losses narrowed compared with the prior-year period, resulting in profit attributable to ...
GENOVA Reshapes Executive Oversight in Key Corporate Divisions
Jun 23, 2026
GENOVA Inc. announced changes in the supervisory responsibilities of its directors and executive officers following an extraordinary board meeting held on June 23, 2026. Director and Executive Officer Sho Inoue will oversee the Business Promotion ...
GENOVA Revises FY2026 Financials After Discovering Classification Errors
Jun 19, 2026
GENOVA Inc. has corrected its consolidated financial results for the fiscal year ended March 31, 2026, after discovering classification errors in its previously disclosed statement. The company reclassified certain cash flows related to business a...
GENOVA Sets Improvement Plan After Falling Short of TSE Prime Listing Standards
Jun 19, 2026
GENOVA Inc. has fallen below the Tokyo Stock Exchange Prime Market’s tradable share market capitalization requirement as of March 31, 2026, and has entered an improvement period ending March 31, 2027 to restore compliance. If it fails to mee...
GENOVA Reshapes Shareholder Structure as Founder Transfers Stake to Asset Firm
Jun 11, 2026
GENOVA Inc. has announced an expected change in its major shareholders after President and Representative Director Tomoki Hirase decided to transfer his entire stake to his asset management company, Hirase Shoten Co., Ltd. The transfers, scheduled...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.